Aurinia Pharmaceuticals Inc Stock News

A whale with a lot of money to spend has taken a noticeably bullish stance on Aurinia Pharmaceuticals . Looking at options history for Aurinia Pharmaceuticals (NASDAQ: AUPH ) we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $106,666 and 7, calls, for a total amount of $216,391. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $13.0 for Aurinia Pharmaceuticals over the last 3 months. Volume … Full story available on Benzinga.com

Takeover speculation has swirled since late 2019 when the company''s lead drug proved to be an effective treatment for lupus nephritis.

A problematic impediment to the sale of Aurinia Pharma has surfaced: The patent life of its drug might not be as strong or long as it hoped.

In the latest trading session, 1.35 million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares changed hands as the company’s beta touched 0.85. With the company’s most recent per share price at $12.09 changed hands at -$0.21 or -1.71% at last look, the market valuation stands at $1.57B. AUPH’s current price is a discount, trading about -180.98% off … Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH): The Stock For Success Over The Next Few Months Read More »

Aurinia topped fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for lupus treatment Lupkynis.

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) is trading significantly lower Monday after the company reported declining fourth-quarter financial results on a year-over-year basis. Aurinia said fourth-quarter revenue totaled $23.4 million, which was down from revenue of $50.03 million year-over-year. The company reported a quarterly earnings loss of 25 cents per share, which was worse than the loss of 6 cents per share in the fourth quarter of 2020. "Despite unpredictable COVID realities, varying … Full story available on Benzinga.com

NEW YORK , Feb. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BP, ZOM, NIO, VEON, and AUPH. … Full story available on Benzinga.com

IntriCon IIN +37%. NeuroSense Therapeutics (NRSN) +28%. Aurinia Pharmaceuticals AUPH -29%. Lexicon Pharmaceuticals LXRX -24%.

The biotech's underwhelming revenue guidance for 2022 is causing some shareholders to throw in the towel today.

The biotech''s underwhelming revenue guidance for 2022 is causing some shareholders to throw in the towel today.

Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical…

Aurinia (AUPH) delivered earnings and revenue surprises of 3.85% and 4.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharma press release (NASDAQ:AUPH): Q4 GAAP EPS of -$0.25 beats by $0.02.Revenue of $23.4M (-53.2% Y/Y) beats by $1.57M.

Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2021 Results - Earnings Call Transcript